Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat

Leukemia and Lymphoma

Volumn 48, Issue 9, 2007, Pages 1667-1669

  Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; VINBLASTINE;

CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; NASOPHARYNX CARCINOMA; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SAFETY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS;

EID: 34548575042     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701606875     Document Type: Note

References (12)

1. Specht, L. (2007) 2-[18F]Fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol, 17, pp. 190-197.
2. Allen-Auerbach, M., Quon, A., Weber, W. A., Obrzut, S., Crawford, T. and Silverman, D. H. (2004) Comparison between 2-deoxy-2-[18F]fluoro-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol, 6, pp. 411-416.
3. Schaefer, N. G., Hany, T. F., Taverna, C., Seifert, B., Stumpe, K. D. and von Schulthess, G. K. (2004) Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology, 232, pp. 823-829.
4. Hoppe, R. T., Adjvani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F. and Djulgegovic, B. NCCN physician guidelines: Hodgkin Disease 2007 v.1
5. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
6. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. and Horning, S. J. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25, pp. 579-586.
7. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T. and Jurlander, J. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, pp. 52-59.
8. Coleman, M. and Kostakoglu, L. (2006) Early 18F-labeled fluoro-2-deoxy-glucose positron emission tomography scanning in the lymphomas: Changing the paradigms of treatments?. Cancer, 107, pp. 1425-1428.
9. Zinzani, P. L., Tani, M., Fanti, S., Alinari, L., Musuraca, G. and Marchi, E. (2006) Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol, 17, pp. 1296-1300.
10. Yahalom, J. (2006) Favorable early-stage Hodgkin lymphoma. J Natl Compr Cancer Network, 4, pp. 233-240.
11. Picardi, M., De Renzo, A. and Pane, F. (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma, 48, pp. 1721-1727.
12. Yahalom, J. (2006) Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol, 24, pp. 544-548.